Spacing out doses, or a lower dose

Why this page exists: this question comes up often in GLP-1 patient forums but rarely in search results. We sampled forum threads by title; we did not quote or identify any user.

What the labels say

Both Wegovy and Zepbound are labelled for once-weekly injection, with specific instructions for missed doses.^[1][2] Spacing doses further apart is outside the label.

Lower dose: one trial

In SURMOUNT-MAINTAIN, people who had lost weight on tirzepatide for 60 weeks were randomly assigned to stay on their full dose, step down to 5 mg, or switch to placebo for a year. They kept 96.5%, 67.9% and 42.8% of their weight loss, respectively. The 5 mg group was still regaining at the end, and the trial lasted only a year.^[3] The trial was funded by the manufacturer.^[3]

SURMOUNT-MAINTAIN, share of lost weight kept after one year of each maintenance approach.^[3]

Spacing and tapering: no trials

We found no completed randomized trial of stretching injection intervals. For gradual tapering, a 2026 meta-analysis noted that the included studies used abrupt stopping only and that guidelines give no specific tapering advice.^[4] The only data are a company-authored conference abstract from a Danish digital clinic, without a comparison group, reporting small average weight change 26 weeks after tapered stopping.^[5] That is too weak to rely on.

Why this matters

Because semaglutide and tirzepatide last about a week and about five days in the body,^[1][2] a longer gap means lower drug levels for part of the cycle, and possibly side effects coming back when doses are resumed. What that does to weight over time has not been measured. If cost, supply or side effects are behind the question, those are all things a prescriber can help with.

The short version

Questions to bring to your prescriber

Print these or screenshot them. They are conversation starters, not a checklist of things to do.

• Is a lower maintenance dose an option for me, and what would we watch for?
• If cost is the problem, what are my options?
• If side effects are the problem, would a slower build-up or a different dose help?

Sources

Every number on this page traces to one of these. "Primary read" means the full paper or label was read; "abstract only" means only the abstract was available; "secondary" means the figure was taken from a named review.

1. Novo Nordisk / FDA. Wegovy (semaglutide) injection and tablets, prescribing information, revised 06/2026. label
2. Eli Lilly / FDA. Zepbound (tirzepatide) prescribing information, revised 08/2026. label
3. SURMOUNT-MAINTAIN: tirzepatide maximum tolerated dose vs 5 mg vs placebo for weight maintenance. Lancet 2026. primary read via Fewer Bites stopping dossier · RCT · industry-funded
4. Qi et al. Weight regain after discontinuation of GLP-1 receptor agonists: meta-analysis. PeerJ 2026. primary read via stopping dossier · meta-analysis
5. Embla (Danish digital clinic). Tapering semaglutide: real-world weight outcomes. European Congress on Obesity 2024 abstract (company-authored). abstract only · observational · not peer-reviewed

Related explainers

All 35 questions